Stop TB Partnership Board Meeting

GLOBAL FUND SESSION
29TH SEPTEMBER 2021
CONTENTS:

1. Global Fund TB Results
2. Global Fund COVID-19 Response Mechanism
3. Country Performance against targets
4. Best practices from C19RM
**TB: State of the Fight in the Time of COVID-19**

Key TB results for 2020 in countries where we invest

- **4.7m**
  People treated for TB – an 18% decrease compared to 2019 due to COVID-19.

- **101,000**
  People on treatment for drug-resistant TB – a 19% decrease compared to 2019 due to COVID-19.

- **194,000**
  Children in contact with TB patients received preventative therapy – a 13% increase compared to 2019 despite COVID-19.

- **271,000**
  HIV-positive TB patients on antiretroviral therapy during TB treatment in 2020 – a 16% decrease compared to 2019 due to COVID-19.
FUNDING REQUESTS AND AWARDS OVERVIEW

C19RM Status of Awards Submissions and Pipeline

84% or US$2,718 million of AFC approved C19RM 2021 funding is awarded or recommended for Board Approval to 108 applicants (either Fast-Track or Full Review) for a portfolio average of 21.9% of HTM allocation.

Full Funding requests: US$2,127 million was awarded or recommended for Board approval to 102 applicants.

Fast-track Funding Requests: US$591 million was awarded to 36 applicants.

Including Unfunded Demand of US$992 million, the total of IC Decisions is up to US$4,156 million. This includes US$446 million of activities not approved.

Demand pipeline: 18% or US$590 million has been submitted or under review for potential C19RM 2021 funding. US$140 million is projected for submission or resubmission.

**Additional contribution from CH and NL subject to AFC approval.**

C19RM Awarded & Requested amounts

<table>
<thead>
<tr>
<th>Total requested amount</th>
<th>IC Decisions</th>
<th>Pipeline*</th>
<th>Available Funds**</th>
<th>Demand in excess of available funds</th>
</tr>
</thead>
<tbody>
<tr>
<td>$4,886</td>
<td>($4,156)</td>
<td>($992)</td>
<td>$3,315</td>
<td>$1,125</td>
</tr>
<tr>
<td></td>
<td>($2,718)</td>
<td>($730)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>($446)</td>
<td>($590)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>($140)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Activities not approved
- Unfunded Demand
- IC awarded
- Received submissions
- Projected submissions/resubmissions

All values are in US$ million and rounded.
For values in screening and under review even incomplete submissions are reported.

*Pipeline includes: submissions under review, in screening, projected resubmissions and remaining eligible applicants.

This week: 3 Full funding requests were awarded for an amount of USD 33.9 million, with 1 pending Board approval.

Requests from 2 countries were approved, for Multicountry HIV EECA APH and Haiti.

Request from 1 is pending board approval, for Russian Federation.
C19RM Award by Priority Area

Award by priority area: Investments are mainly directed towards reinforcing COVID-19 national response.

Out of the Full Funding Requests awarded or recommended for Board approval, we continue to see prioritization of reinforcing the COVID-19 national response likely due to the rapid increase in cases across a number of countries.

All values in the charts are in US$ million and rounded. Program management costs are included in Reinforce. Recent awards values may be adjusted slightly once Detailed Budgets are finalized. Values above include Fast-track awards and Full Funding Requests awarded and/or recommended for Board approval.
Global Fund Results Report 2021
Impact of COVID-19: 1.4 million fewer people treated

- With similar symptoms such as cough, fever and breathing difficulties, TB and COVID-19 can be confused; many people with TB symptoms avoided health clinics or were turned away due to stigma and fear.

- Treatment dropped by 18% across all countries where the Global Fund invests, with high-burden countries severely hit.

- Countries like Nigeria and DRC managed slight increases.
Overall performance for the 20 priority countries declined by 18% compared to 2019. **1 million fewer cases** notified compared to 2019 in these countries. Asian countries most impacted. These countries represent **87% of GF results in 2020** (people with TB treated).
Mitigating the impact on TB

• To end both COVID-19 and TB as epidemics, we must fight both diseases at the same time, increasing investments in the same tools, health workers and systems for health needed to fight TB and COVID-19 and prepare for future airborne pandemics.

• The same tools the Global Fund partnership has built to fight TB are now being used to fight COVID-19, and emergency funding from the Global Fund to mitigate the impact of COVID-19 on TB programs and reinforce systems for health has helped countries to continue to fight TB at the same time as fighting COVID-19.

• Two TB Information Notes developed with partners - “catch-up’ plan in Nov 2020, updated for C19RM application materials in May 2021
C19RM Investments in Mitigation

- Of the US$2,127 million awarded for Full Funding Requests (including recommendations for Board approval), US$289 million (13.6%) is invested in mitigating the impact of COVID-19 on HIV, TB and malaria programs.
- Investments in mitigating the impact of COVID-19 are primarily covered within the core HIV, TB, malaria grants (2020-2022 allocation); Malaria grants (2020-2022 allocation) incorporated a significant amount of PPE needs for mass campaigns and community activities.

Awards in Mitigation for Full Funding Requests

- US$108 million (38%) for HIV/AIDS
- US$102 million (35%) for TB
- US$78 million (27%) for malaria

DISRUPTION TO HIV, TB AND MALARIA SERVICES (as of Sept 24)
# Priority mitigation interventions requested by countries

The Global Fund has approved over $100 million towards TB Mitigation under C19RM (as of 17 Sept)

| Training & Protecting Health care workers (including community health workers) |
| Community, home-based and people centered models of care |
| Strategic use of COVID-19 control measures |
| Bi-directional screening/testing |
| Improved access to rapid molecular tests. |
| Digital Adherence Technologies |
| Sample transportation modifications |
| Integrated TB/COVID-19 contact investigations |
| Social protection |
| Use of digital chest x-ray, Computer Aided Detection with AI |
Thank you